Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Miles Murphy

Urogynecology and Reconstructive Pelvic Surgery Allentown, PA Medical Doctor

NPI 1699701623 CMS profile 349478

3050 Hamilton Blvd., Suite 200, Allentown, PA 18103

Open in the dashboard

General payments

$53,802

417 records reported · program years 2019–2025

Research payments

$749

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$146,552 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Miles Murphy of Allentown, PA is reported in the CMS Open Payments database as having received $53,802 across 417 general payments and $749 in research payments paid to them. Separately, studies naming them as principal investigator received $146,552 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,371 64
2024 General $2,271 61
2023 General $1,737 45
2022 General $2,691 72
2021 General $2,265 56
2021 Research $749 1
2020 General $4,083 46
2019 General $37,384 73

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Miles Murphy
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Miles Murphy were reported at $3,371. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.

Show as a table
Year Miles Murphy Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $37,384 $358 $132–$1,270 $163
2020 $4,083 $198 $86–$642 $114
2021 $2,265 $361 $118–$1,182 $132
2022 $2,691 $410 $128–$1,175 $149
2023 $1,737 $434 $152–$1,344 $160
2024 $2,271 $494 $193–$1,331 $164
2025 $3,371 $412 $133–$1,300 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $42,652 49 payments
  2. Coloplast Corp $2,291 49 payments
  3. Astellas Pharma US Inc $1,625 72 payments
  4. AbbVie, Inc. $1,198 54 payments
  5. Medtronic, Inc. $1,037 16 payments
  6. Axonics Modulation Technologies, Inc. $961 54 payments
  7. Teleflex LLC $730 4 payments
  8. Caldera Medical, Inc $696 15 payments
  9. ZOLL Medical Corporation $492 1 payment
  10. Pfizer Inc. $398 30 payments
  11. Other $1,723 73 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $28,804 16 payments
  2. Food and Beverage $8,962 361 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,200 3 payments
  4. Travel and Lodging $7,002 13 payments
  5. Education $867 16 payments
  6. Honoraria $700 2 payments
  7. Entertainment $136 4 payments
  8. Gift $133 2 payments
Products named General payments · program years 2019–2025
  1. CROSSBOSS $29,802 10 payments
  2. GENERAL THERAPIES $6,041 10 payments
  3. GENERAL - PELVIC ORGAN PROLAPSE $3,038 4 payments
  4. Altis Women's Health $1,172 21 payments
  5. ALTIS Female Incontinence $946 22 payments
  6. BOTOX $932 42 payments
  7. ALTAVIVA $911 10 payments
  8. General - Female SUI $750 1 payment
  9. BARRIGEL $700 2 payments
  10. MYRBETRIQ $610 45 payments
  11. Other $6,650 265 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Coloplast Corp $749 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

1,544

Median for Obstetrics & Gynecology: 65

Drug cost

$332,248

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

58.7%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 275 $185,717
Gemtesa Vibegron Brand 109 $81,876
Elmiron Pentosan Polysulfate Sodium Brand 16 $15,717
Premarin Estrogens, Conjugated Brand 27 $11,519
Methenamine Hippurate Generic 99 $9,235
Estradiol Generic 113 $6,636
Trospium Chloride Er Trospium Chloride Brand 35 $5,875
Solifenacin Succinate Generic 186 $5,067
Fesoterodine Fumarate Er Fesoterodine Fumarate Brand 19 $2,510
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 230 $2,217

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$193,924

Medicare's payments for the services billed

Medicare patients

349

Average age 75

Services billed

1,819

349 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 63%
Osteoporosis 36%
Depression 25%
Ischemic heart disease 21%
Chronic kidney disease 20%
Diabetes 18%
Cancer 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $357
$357 — —
Veozah
  • Astellas Pharma US Inc $225
$225 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $155
$155 109 —
MYFEMBREE
  • PFIZER INC. $31
$31 — —
BLUDIGO
  • Provepharm Inc. $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

418 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record